Precigen: Full Commercial Validation And Room To Run
Precigen Q1 Earnings Call Highlights
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen (NASDAQ:PGEN) Shares Gap Up on Analyst Upgrade
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Precigen Reports Full Year 2025 Financial Results and Business Updates
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Hold” by Brokerages
Precigen: PAPZIMEOS Is Delivering For This Under-The-Radar Biotech
Precigen, Inc. (NASDAQ:PGEN) Receives Average Recommendation of “Hold” from Brokerages
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?
Precigen Is Still A Buy After The Papzimeos Rally
Precigen (NASDAQ:PGEN) Stock Price Up 28.9% on Analyst Upgrade
Precigen Sees Unusually Large Options Volume (NASDAQ:PGEN)
Precigen, Inc. (PGEN) Q3 2025 Earnings Call Transcript
Precigen Reports Third Quarter 2025 Financial Results and Business Updates
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13
Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares
Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
Precigen Announces Up to $125 Million Non-Dilutive Financing
Precigen, Inc. - Special Call
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright
Undercovered Dozen: Precigen, ONEOK, Bitmine And More
Precigen price target raised to $8 from $6 at Citizens JMP
Precigen: This Billion-Dollar Approval Is Still Undervalued
Why Is Precigen Stock Surging On Friday?
US FDA approves Precigen's immunotherapy for rare respiratory disease
Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Precigen: August Is Pivotal For This Biotech Innovator
Precigen Reports First Quarter 2025 Financial Results and Business Updates
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
Precigen Reports Full Year 2024 Financial Results and Business Updates